Medigen Vaccine Biologics Corporation, a biopharmaceutical company, develops and produces vaccines and biologics for unmet medical needs in Taiwan and internationally. More Details
+ 1 more risk
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Medigen Vaccine Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6547 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 6547's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
7 Day Return
1 Year Return
Return vs Industry: 6547 exceeded the TW Biotechs industry which returned 21.7% over the past year.
Return vs Market: 6547 exceeded the TW Market which returned 28.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Medigen Vaccine Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWould Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?
4 months ago | Simply Wall StIs Medigen Vaccine Biologics (GTSM:6547) Using Debt In A Risky Way?
8 months ago | Simply Wall StAnnouncing: Medigen Vaccine Biologics (GTSM:6547) Stock Increased An Energizing 137% In The Last Three Years
Is Medigen Vaccine Biologics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6547's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6547's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6547 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 6547 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6547's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6547 is overvalued based on its PB Ratio (13.8x) compared to the TW Biotechs industry average (4.8x).
How is Medigen Vaccine Biologics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigen Vaccine Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of 6547’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Medigen Vaccine Biologics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6547 is currently unprofitable.
Growing Profit Margin: 6547 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6547 is unprofitable, and losses have increased over the past 5 years at a rate of 29.6% per year.
Accelerating Growth: Unable to compare 6547's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6547 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 6547 has a negative Return on Equity (-48.34%), as it is currently unprofitable.
How is Medigen Vaccine Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: 6547's short term assets (NT$483.0M) exceed its short term liabilities (NT$183.8M).
Long Term Liabilities: 6547's short term assets (NT$483.0M) do not cover its long term liabilities (NT$636.3M).
Debt to Equity History and Analysis
Debt Level: 6547's debt to equity ratio (29%) is considered satisfactory.
Reducing Debt: 6547's debt to equity ratio has increased from 19.5% to 29% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6547 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 6547 has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.9% each year.
What is Medigen Vaccine Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6547's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6547's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6547's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6547's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6547's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Medigen Vaccine Biologics has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.3%.
Medigen Vaccine Biologics Corporation's company bio, employee growth, exchange listings and data sources
- Name: Medigen Vaccine Biologics Corporation
- Ticker: 6547
- Exchange: GTSM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$21.849b
- Shares outstanding: 211.10m
- Website: https://www.medigenvac.com
Number of Employees
- Medigen Vaccine Biologics Corporation
- No. 16, Neihu Road
- 7th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6547||GTSM (Taipei Exchange)||Yes||Common Shares||TW||TWD||Aug 2015|
Medigen Vaccine Biologics Corporation, a biopharmaceutical company, develops and produces vaccines and biologics for unmet medical needs in Taiwan and internationally. The company is developing A 71 to fig...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/21 17:29|
|End of Day Share Price||2021/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.